Polypeptide With Localisation/Targeting Motif TRIZ Cases

Tricistronic constructs encoding anti-B7-H4 CARs and interleukin-2 reduce exogenous cytokine requirements while extending cytotoxicity duration.

Engineered commensal bacteria continuously secrete recombinant polypeptides directly on the skin surface.

Enhanced dual-GRASP system uses split-fluorescent proteins to label intercellular proximities with increased brightness.

Ligand-coated supports stimulate CAR immune cells to resolve assay precision and reproducibility bottlenecks in GMP manufacturing.

Engineered cells secrete therapeutic proteins in response to physiological cues, eliminating frequent injections.

Dual display vectors express membrane-bound and secreted immunoglobulins to isolate high-expressing cells.

A1R-CT peptide blocks neurabin interaction to enhance adenosine receptor activity.

Engineered amphipathic peptides disrupt resistant bacterial membranes via electrostatic binding, neutralizing pathogens without mammalian toxicity.

Truncating the Cas9 protein resolves adeno-associated virus packaging constraints, enabling multiplex viral genome editing.

Engineered CAR constructs target Glypican-3 on hepatocellular carcinoma cells, resolving specificity and efficacy trade-offs in immunotherapy.

Segmenting avidin into dual chains resolves inconsistent refolding by enabling independent affinity tuning across subunits.

A single chain VH antibody construct links a variable domain to constant domains via peptidic linkers.

CD19_12.18 antibody targets a distinct CD19 epitope to overcome resistance in chimeric antigen receptor therapies.

Non-human animals with a humanized TTR locus express human transthyretin protein for in vivo therapeutic reagent assessment.

CAPER peptides bind c-Jun and estrogen receptor alpha to induce apoptosis, addressing limited triple negative breast cancer treatment options.

Novel linker sequences enable cytokine receptor fusion proteins to bind target ligands with optimal affinity and spatial precision.

A CD40-targeted trimeric MERS-CoV S1 fusion polypeptide elicits robust neutralizing antibody responses through specific antigen-presenting cell delivery.

Ionizable lipid nanoparticles deliver DNA sequences to target tissues, maintaining protein levels for months while reducing host immunogenic responses.

Reporter immune cells track CAR T cell biodistribution via PET imaging to overcome solid tumor resistance.

Modified splice acceptor sites regulate splicing ratios to produce both soluble and membrane-bound immunoglobulins, streamlining high producer clone selection.

STEMIN polypeptides convert fibroblasts into functional cardiomyocytes, bypassing prolonged stem cell culture times and ethical risks.

Replacing CD3ζ domains with Fcγ signaling reduces off-tumor toxicity while maintaining anti-tumor efficacy in gamma delta T cell therapies.

Isolated immunogenic peptides induce regulatory T cells to suppress immune responses against transplanted tissue.

Protease-cleavable linkers activate cytokines in diseased tissues, reducing systemic toxicity and expanding the therapeutic window.

Inducing expression during logarithmic growth prevents inclusion body formation, ensuring high yields of soluble, immunogenic HIV-1 Tat protein.

Dexamethasone addition in fed-batch processes maintains sialic acid content and reduces protein aggregation during extended culture phases.

A nucleic acid construct uses frame-slip motifs to regulate downstream transgene translation within a single vector.

Secreted alpha-1,6-glucosidase breaks down isomaltose and panose into glucose, eliminating Maillard reactions that reduce L-lysine yield.

Fully human anti-mesothelin antibodies link with chimeric antigen receptors to target tumor cells.

Targeting ROR2 expression overcomes crizotinib resistance in ALK-positive anaplastic large cell lymphoma.

Single-domain antibody domains in chimeric engagers resolve species specificity and safety issues while enhancing T cell cytotoxicity.

Recombinant baculoviruses display EV71 capsid proteins to stimulate strong immune responses without handling virulent pathogens.

Shark VNAR single-domain antibodies bind PD-L1 on solid tumors, blocking PD-1 interaction to reduce T cell exhaustion and improve cytotoxicity.

Merging Spike RBD with Nucleocapsid in a chimeric protein overcomes variant vulnerability by inducing broad antibody and cellular immunity.

An anti-C3d antibody binds complement protein C3d deposited on cancer cell surfaces to trigger immune-mediated destruction.

VAR2CSA-fused CARs and split-protein binding systems enable precise immune response activation against cancer cells.

Antibody constructs bind histone H3 peptide and MHC class I complexes, enabling targeted recognition of pediatric glioma cells with mutant histone proteins.

A bedside closed-loop system modifies nucleated blood cells in vivo through continuous-flow separation and targeted agent delivery.

Segmented iCAR and pCAR receptors detect loss of heterozygosity to eliminate tumor cells while sparing normal tissue.

A CD38-directed chimeric antigen receptor construct uses differential binding affinity to selectively target tumor cells.

Sortase enzymes mediate site-specific protein conjugation on living cells, resolving the trade-off between modification precision and genetic complexity.

Cascade complex and Cas3 polypeptide resolve low large deletion frequency by enabling targeted nucleic acid degradation via homologous recombination.

LILRB1-based chimeric antigen receptors use ITIM motifs to resolve the contradiction between killing activity and specific cell type restriction.

CD8a hinge and transmembrane domains in CAR constructs enable bone marrow homing, reducing severe side effects while maintaining antitumor activity.

Nuclear localization signal peptides selectively upregulate TNFR2 expression to competitively inhibit TNFR1 binding and reduce apoptosis.

A Mannose-6-phosphate bearing peptide fused to lysosomal enzymes enables targeted cellular delivery.

Codon-optimized chimeric T cell receptors enhance specificity and efficacy against cancer cells.

Shp2-iSNAP chimeric proteins rewire the CD47/SIRPα axis to activate macrophage phagocytosis of tumor cells.